Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NKGen Biotech ( (NKGN) ) just unveiled an update.
On May 5, 2025, NKGen Biotech entered into a Stock Purchase Agreement with its CEO and Chairperson, Paul Y. Song, involving the sale of 20,849,725 shares and warrants to purchase additional shares, valued at $2.65 million. This investment aims to accelerate the company’s Phase 2 clinical trial for Alzheimer’s Disease and address financial obligations. The transaction, approved by the Board and Audit Committee, reflects confidence in NKGen’s potential and aligns with the company’s strategic objectives.
More about NKGen Biotech
NKGen Biotech, Inc. is a clinical-stage biotechnology company based in Santa Ana, California, focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics.
Average Trading Volume: 3,820,537
Technical Sentiment Signal: Sell
Current Market Cap: $5.95M
Find detailed analytics on NKGN stock on TipRanks’ Stock Analysis page.